Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00644839 · ClinicalTrials.gov registry record · Phase 1
Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00644839 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 28 participants.
The verdict
NCT00644839, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Experiment in the test tube indicated that CP-945,598 becomes less soluble with increase of pH (less acidity). Changes in stomach acid levels may affect the solubility of CP-945,598, therefore, alters its availability in the blood. Omeprazole decreases acid levels in stomach. This study will compare the time course of drug concentrations in the body, safety, and tolerability of CP-945,598 given with and without omeprazole.
Interventions
- DRUG CP-945,598
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00644839
The ClinicalTrials.gov registry entry for NCT00644839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-945,598 is the first listed.
NCT00644839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00644839 about?
NCT00644839 is a clinical study titled "Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug". Experiment in the test tube indicated that CP-945,598 becomes less soluble with increase of pH (less acidity). Changes in stomach acid levels may affect the solubility of CP-945,598, therefore, alters its availability in the blood. Omeprazole decreases acid levels in stomach. This study will compare...
What is the current status of trial NCT00644839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2008-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00644839?
The interventions under investigation include: CP-945,598 (DRUG).
Who is sponsoring clinical trial NCT00644839?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.